These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38534703)

  • 21. Commensal
    Almoughrabie S; Cau L; Cavagnero K; O'Neill AM; Li F; Roso-Mares A; Mainzer C; Closs B; Kolar MJ; Williams KJ; Bensinger SJ; Gallo RL
    Sci Adv; 2023 Aug; 9(33):eadg6262. PubMed ID: 37595033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.
    Molinelli E; De Simoni E; Candelora M; Sapigni C; Brisigotti V; Rizzetto G; Offidani A; Simonetti O
    Antibiotics (Basel); 2023 May; 12(6):. PubMed ID: 37370297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hidradenitis suppurativa presents a methylome dysregulation capable to explain the pro-inflammatory microenvironment: Are these DNA methylations potential therapeutic targets?
    Radhakrishna U; Ratnamala U; Jhala DD; Uppala LV; Vedangi A; Patel M; Vadsaria N; Shah S; Saiyed N; Rawal RM; Mercuri SR; Jemec GBE; Damiani G
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2109-2123. PubMed ID: 37338327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.
    Liu H; Santos LL; Smith SH
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Kimball AB; Jemec GBE; Alavi A; Reguiai Z; Gottlieb AB; Bechara FG; Paul C; Giamarellos Bourboulis EJ; Villani AP; Schwinn A; Ruëff F; Pillay Ramaya L; Reich A; Lobo I; Sinclair R; Passeron T; Martorell A; Mendes-Bastos P; Kokolakis G; Becherel PA; Wozniak MB; Martinez AL; Wei X; Uhlmann L; Passera A; Keefe D; Martin R; Field C; Chen L; Vandemeulebroecke M; Ravichandran S; Muscianisi E
    Lancet; 2023 Mar; 401(10378):747-761. PubMed ID: 36746171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consistency of Bacterial Triggers in the Pathogenesis of Hidradenitis Suppurativa.
    Rosi E; Guerra P; Silvi G; Nunziati G; Scandagli I; Di Cesare A; Prignano F
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hidradenitis Suppurativa: Absence of Hyperhidrosis but Presence of a Proinflammatory Signature in Patients' Sweat.
    Frings VG; Roth N; Gläsel M; Bauer B; Goebeler M; Presser D; Kerstan A
    Acta Derm Venereol; 2022 Oct; 102():adv00793. PubMed ID: 36172698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa.
    Radhakrishna U; Ratnamala U; Jhala DD; Vadsaria N; Patel M; Uppala LV; Vedangi A; Saiyed N; Rawal RM; Damiani G; Jemec GBE
    J Invest Dermatol; 2023 Apr; 143(4):670-673.e19. PubMed ID: 36155054
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.
    Kozera E; Flora A; Frew JW
    J Am Acad Dermatol; 2022 Dec; 87(6):1440-1442. PubMed ID: 35934210
    [No Abstract]   [Full Text] [Related]  

  • 30. Methylated miRNAs may serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa.
    Radhakrishna U; Ratnamala U; Jhala DD; Vadsaria N; Patel M; Uppala LV; Vishweswaraiah S; Vedangi A; Saiyed N; Damiani G; Jemec GBE
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2199-2213. PubMed ID: 35921387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into hidradenitis suppurativa.
    van Straalen KR; Prens EP; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Apr; 149(4):1150-1161. PubMed ID: 35189127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
    Alavi A; Hamzavi I; Brown K; Santos LL; Zhu Z; Liu H; Howell MD; Kirby JS
    Br J Dermatol; 2022 May; 186(5):803-813. PubMed ID: 34978076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapsone in hidradenitis suppurativa: A case series of 56 patients.
    López-Llunell C; Riera-Martí N; Gamissans M; Romaní J
    Dermatol Ther; 2021 Nov; 34(6):e15161. PubMed ID: 34665504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial peptides in hidradenitis suppurativa: a systematic review.
    Yao Y; Frew JW; Thomsen SF; Ring HC
    Br J Dermatol; 2022 Feb; 186(2):236-244. PubMed ID: 34498267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
    JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coagulase-negative staphylococci release a purine analog that inhibits Staphylococcus aureus virulence.
    Chin D; Goncheva MI; Flannagan RS; Deecker SR; Guariglia-Oropeza V; Ensminger AW; Heinrichs DE
    Nat Commun; 2021 Mar; 12(1):1887. PubMed ID: 33767207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy.
    Iannone M; Janowska A; Bartolomei G; Puntoni M; Oranges T; Romanelli M; Dini V
    Dermatol Ther; 2021 May; 34(3):e14919. PubMed ID: 33634552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
    van Straalen KR; Tzellos T; Guillem P; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Jemec GBE; Katoulis AC; Koenig A; Lazaridou E; Marzano AV; Matusiak Ł; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Romaní J; Saunte DM; Skroza N; Stergianou D; Szepietowski J; Trigoni A; Vilarrasa E; van der Zee HH
    J Am Acad Dermatol; 2021 Aug; 85(2):369-378. PubMed ID: 33484766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Microbiome in Hidradenitis Suppurativa: A Review.
    Wark KJL; Cains GD
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):39-52. PubMed ID: 33244661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aetiology and pathogenesis of hidradenitis suppurativa.
    Wolk K; Join-Lambert O; Sabat R
    Br J Dermatol; 2020 Dec; 183(6):999-1010. PubMed ID: 33048349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.